NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting
April 08 2019 - 10:00AM
InvestorWire
Clinical-stage gene therapy company Genprex Inc.
(NASDAQ: GNPX) this morning announced that its collaborators
from the University of Texas MD Anderson Cancer Center (“MD
Anderson”) detailed positive preclinical data, in a poster
presented at the American Association of Cancer Research Meeting
2019, regarding the combination of the TUSC2 gene with an anti-PD1
antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is
a tumor suppressor gene and the active agent in Genprex’s Oncoprex
immunogene therapy.
“Development of an improved humanized patient-derived xenograft,
Hu-PDX, mouse model for evaluation of antitumor immune response in
lung cancer,” was the title of the poster, which demonstrated that
TUSC2 combined with checkpoint blockade was more effective than
checkpoint blockade alone in increasing the survival of mice with
human immune cells (humanized mice) that had metastatic lung
cancer. The data showed that TUSC2 treatment with checkpoint
inhibitor pembrolizumab worked to significantly slow tumor growth.
Previously, pembrolizumab had no effect on tumor growth in
non-humanized mice. The data also demonstrated the Hu-PDX model as
an improved platform for immunotherapy evaluation.
“This sophisticated model gets one step closer to recapitulating
certain functions of the human immune response within a manageable
scientific animal model and allows us to further test our
hypotheses of how a more complex immune system could interact with
aggressive cancers when primed by drugs, such as Oncoprex, in
humans,” Genprex President and COO Julien L. Pham, MD, MPH, stated
in the news release. “These data further support and solidify
existing preclinical data showing that Oncoprex immunogene therapy
is synergistic with anti-PD1 therapy and could result in a stronger
antitumor response compared to either agent alone. It also
demonstrates how Oncoprex could be used in combination with other
immunotherapies as a viable treatment option for late-stage
non-small cell lung cancer.”
To view the full press release, visit http://nnw.fm/0dotF
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. For more information, visit
the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at
http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024